text:
Pharma Report 2012: Get Back in Shape
When big pharma looks in the mirror, what does it see? A body beset by old, expiring brands and not enough energetic, youthful ones to replace them. Marc Iskowitz has industry's regimen for regaining form
Once bloated and winded, the drug industry has made strides at shaping up its US operations, shedding excess pounds and taking steps to shore up long-term health. That's a start. Getting back into real shape will take a package of exercises that build muscle in more ways than one, analysts say.
Industry had a positive 2011, with spending on branded products in the US up by 2.2% in actual dollars to $258 billion from $252 billion, according to IMS Health. It bettered 2010, when spending on protected medicines shrunk 0.7% to $229 billion, and it helped boost overall drug outlay by 3.7% to $320 billion for the year.
New product launches, many of them for innovative medicines and indications to treat rare diseases, helped fuel the increase. But patent losses continue to bite. The glut of expiries is set to reduce global brand revenues by $120 billion through 2015.
Those losses will be felt the most this year and next, predicts Michael Kleinrock, director of research development for the IMS Institute. "Brand growth will be historically low," in the 0-1% range.
Perhaps the most important trend to watch in terms of the industry's comeback lies in new drug pipelines. These may be slowly improving, yet no company has more upcoming launches than expiries, Sanford Bernstein analyst Tim Anderson tells MM&M: "GlaxoSmithKline starts to get into positive territory because their patent expiries lapse. Pfizer—any drug that they launch, or that launched, [when] netted against expiry is a flat line." Even Bristol-Myers Squibb—widely hailed as the most productive biopharma company—winds up being a flat-liner.
In the following profiles of the top 20 companies as ranked by 2011 US sales, you can judge the performance for yourself. In addition to revenues, US and global; top brands and their US sales (courtesy of IMS); and promotional spend (as per Cegedim Strategic Data; ranking encompasses US sales top 20 vs. ranking on pp. 44-45 based purely on promo spend), we include a list of each firm's planned launches—late-stage compounds that analysts believe stand a strong chance of making it to the US market—and upcoming patent expirations.
Pfizer's oral RA drug tofacitinib and Eliquis (apixaban), the blood-thinning drug Pfizer is co-developing with BMS, are the high-profile agents coming due in 2012. There will also be pivotal data sets this year, the most dramatic being in Alzheimer's disease, although the category lacks a launchable drug in 2012.
"If these Alzheimer's drugs work [Lilly's solanezumab and J&J/Pfizer's bapineuzumab]," says Anderson, "they would put the industry back on the map, but scientists put the odds at less than 50%. These drugs could help resurrect the image of the industry."
Putting money into R&D
Among other steps companies are taking to get back into shape, most plowed more money into R&D last year, despite the fact that it's hard to scale innovation. Our company profiles rank firms on their actual R&D spend, indicating the change vs. 2010, and calculate spend as a percentage of revenue.
Pfizer, for one, did not follow the pack in this department. "Pfizer could theoretically spend less and get the same output, which is why they are ratcheting down their R&D spend," says Anderson.
Profiles also show what's emerging from pipelines, as does the approvals table on page 50. Drilling down into last year's newbies, Healogix CEO Harris Kaplan notes that only 23% of 2011 approvals were for drugs with new mechanisms of action vs. almost 60% in 2002. And orphan drug approvals—which were up last year—aren't a replacement for better chronic therapy treatment.
"While orphan drugs with their associated high prices are helping to fill the gap caused by generic expirations," says Kaplan, "they do not substitute for an ongoing patient and industry need for new advances in large, chronic disease categories where there is still significant unmet need such as hypertension, depression, GI disorders, etc."
Industry can pat itself on the back for a productive 2011 both in terms of drugs approved (30, vs. 23 in 2010) and the therapeutic advances they represent, but one year is not a trend, cautions Wayne Pines, a former FDA associate commissioner who is now president, regulatory services and healthcare for APCO Worldwide.
"I don't think the approval numbers indicate anything significant about FDA," says Pines. "The agency can approve new drugs only when the data meet its standard for safety and effectiveness."
Pines and Kaplan say they're more concerned that these innovative drugs get reimbursed. Kaplan says payers are beginning to push back on reimbursing drugs costing patients well into six figures per year.
Another strategy companies continue to employ to fill revenue gaps is M&A, like Sanofi's acquisition of consumer health firm Chattam last year. The easiest way to replace lost sales, these are likely to continue, says Anderson.
Of course, many firms continue to trim their bottom line through wave after wave of job cuts and corporate reorganizations. "In terms of cost-cutting, these companies have a long way to go before they've cut to the bone," says Anderson. He expects more of the same operationally in all buckets—including sales force and R&D.
But the most significant predictors of financial health include more than just a company's willingness to diet. A big one is the firm's degree of diversification into areas like consumer and animal health—businesses that are not subject to the pushes and pulls of the pharma business. "If you broadened it out," says Anderson, "Abbott and J&J are most diversified and have had the best stock performance."
Another leading indicator is the durability of companies' product lines, i.e., how high is the line's barrier to entry. "Animal health and vaccines—they are oligopolies," says Anderson, in that competition is less and they don't have generics issues.
Exposure to emerging markets is a third important variable, as everyone agrees that their future growth is likely to outpace US and Europe. European companies like Sanofi, GSK and Novartis have the most exposure, while for domestics like BMS and Eli Lilly, it's 10% or less.
Again, don't look for this to be industry's magic pill. "Those that are reaching out to new geographies are making 50 cents on the dollar," says Anderson, "but that is better than making no cents on the dollar. It is almost like the industry is pulling out the couch cushions to look for spare change."
Revenues, brands, media spend, patent expirations and drug approvals
1. Pfizer (see below)
1 Pfizer $25.1B down 7.7%
Global revenue: $67.4B (1st); up 0.4%
R&D spend: $8.4B (3rd); down 9.7%; 12.5% of rev.
Top brands: Lipitor ($7.7B), Lyrica ($1.8B), Celebrex ($1.8B), Geodon ($1.4B), Viagra ($1.0B)
Planned launches: Eliquis (SPAF), tofacitinib (RA)
Promotional spend: $2.2B (1st); 8.6% of rev.
Patent expirations: Lipitor (2011), Celebrex (2014), Zyvox (2015)
Pfizer has pretty much made it past a chasm of a patent cliff with relatively minor adjustments, and now boasts one of the best late-stage pipelines. It recently won approval for cancer drugs Xalkori (crizotinib) and Inlyta (axitinib) along with a label expansion for vaccine Prevnar 13. Waiting in the wings are rheumatoid arthritis drug tofacitinib and anticoagulant Eliquis (apixaban)—a JV with BMS for stroke prevention that analysts have high hopes for, despite an FDA delay. The biggest of pharmas acquired Wyeth in 2009 and King in 2010, and last year lost exclusivity for $10-billion mega-blockbuster Lipitor—along with two-thirds of the statin's market share, despite an aggressive defense. CEO Ian Read floated plans for a big shakeup, but ended up placing only Pfizer's animal health and nutrition units on the block. Pipeline wins haven't quieted calls for more aggressive action—most recently Goldman analyst Jami Rubin's call for a full-scale Abbott-style spin-off.
2 AstraZeneca $19.9B up 2.1%
Global revenue: $33.6B (9th); up 0.9%
R&D spend: $5.0B (8th), up 19%; 14.9% of rev.
Top brands: Seroquel IR ($3.3B); Crestor ($3.1B); Nexium ($2.4B); Symbicort ($846M)
Planned launches: Fostamatinib (arth.): NKTR-118 (constipation)
Promotional spend: $1.3B (4th); 6.9% of rev.
Patent expirations: Seroquel IR (2012); Nexium (2014); Symbicort (2015); Crestor (2016)
AstraZeneca faces one of the steepest revenue declines of the pharma majors. Combined with a pipeline analysts consider anemic at best, analysts talk about an acquisition as being a necessary lifeboat for the firm. Most recently, AZ abandoned its depression medication known as TC-5214 after the compound missed its Phase III primary endpoint. A back-and-forth patent drama over anti-psychotic Seroquel, whose IR form goes off patent later this year, yielded a bit of good news: a US judge asserted that the extended-release version would remain covered until 2017 (although the UK High Court declared that Seroquel XR no longer had protection). The company's present outlook is one of hunkering down: besides multiple waves of job cuts, the firm shuttered at least one R&D location. Its fourth-quarter 2011 earnings call was an unvarnished one: CEO David Brennan acknowledged the pipeline is underperforming, while CFO Simon Lowth said significant revenue declines are in store.
3 Merck $19.3B up 3.8%
Global revenue: $48.0B (4th); up 4.3%
R&D spend: $7.7B (4th), down 4.9%; 16% of rev.
Top brands: Singulair ($4.5B); Januvia ($2.1B); Zetia ($1.3B): Vytorin ($1.1B)
Planned launches: Vorapaxar (TRA); Tredaptive & MK-0524B (athero.); odanacatib (osteo.)
Promotional spend: $1.3B (3rd); 7.0% of rev.
Patent expirations: Singulair (2012); Avelox (2014); Nasonex (2014)
Merck performed well domestically and globally, thanks in large part to the Januvia diabetes franchise, which now accounts for 76% of the global DPP-IV market. This franchise will keep growing from almost $5.9B (globally) to $9.4B by 2016, Bernstein's Tim Anderson predicts, helping offset top seller Singulair's loss of exclusivity this year and plugging shortfalls in other franchises, like Isentress, which is at risk due to HIV/AIDS competition from Gilead and GSK/Shionogi; Remicade, whose revenues are declining after some control was ceded to partner J&J in 2010; and cholesterol meds Vytorin and Zetia, down about 45% in US sales since the 2008 Enhance study, and which face a renewed threat from generic Lipitor. Whether the ezetimibe franchise gets vindicated by the IMPROVE-IT trial won't impact P&L too much. What matters more is whether late-stage pipeline drugs suvorexant (sleep), odanacatib (osteo.), vorapaxar (TRA) and Tredaptive stay on track.
4 Novartis $19.2B up 6.7%
Global revenue: $58.5B (3rd); up 15.6%
R&D spend: $9.2B (1st), up 13.6%; 15.7% of rev.
Top brands: Diovan/Co-Diovan ($2.3B); Gleevec ($1.5B); Zometa ($642M); Sandostatin ($574M)
Planned launches: Bexsero (men. B vacc.); Seebri Breezhaler (NVA237)/QVA149 (COPD)
Promotional spend: $973M (6th); 5.1% of rev.
Patent expirations: Diovan (2012); Zometa (2013); Gleevec (2015)
Novartis is bracing for some ugly patent exclusivity losses, with blockbuster Femara having gone off patent and $2.3-billion Diovan, the company's top seller, facing generic competition in September. Next year, $642-million Zometa goes over the patent cliff, and in 2015, $1.5-billion Gleevec loses exclusivity. But the Swiss giant has cobbled together an Alpine portfolio from steadily-performing smaller brands while diversifying its business into generics (Sandoz), vaccines and diagnostics and, most recently, vision care with its acquisition of Alcon in 2010. The company boasts a muscular R&D operation, as evidenced by MS drug Gilenya, a likely blockbuster approved in 2010, and Arcapta Neohaler for COPD, approved in July, along with a robust late-stage pipeline. However, Novartis has been plagued by manufacturing issues at plants in Quebec and Nebraska. Other potential pitfalls include safety concerns about Gilenya that could hamper that key product's potential, and FDA delays on approvals of the Menveo vaccine and Seebri Breezhaler (NVA237).
5 Teva $15.1B down 5%
Global revenue: $18.3B (12th); up 13.7%
R&D spend: $1.1B (18th), up 18.3%; 6% of rev.
Top brands: Copaxone ($3.0B); Provigil ($1.1B), ProAir HFA ($953M), budesonide ($856M)
Planned launches: Custirsen (onc.); neugranin (onc.); Revascor (CV)
Promotional spend: $257M (16th); 1.7% of rev.
Patent expirations: Copaxone (2014), Treanda (2015)
This multi-billion dollar company is proof that generics can be big business. Although Teva saw its North America earnings power shrink to 48% of its sales in 2011 from 62% in 2010, the Israeli company balanced things out, increasing sales to 31% in Europe, up from 24% in 2010, and hauled in 21% of its take from international sales, compared with 14% the year before. Although the company remains solidly in the unbranded drug space, its $6.8-billion purchase last year of Cephalon and its CNS portfolio means more exposure to the brand side of the patent-protection wars, as CNS drugs Provigil, Copaxone and Treanda burn through their exclusivity periods. Teva dealt Par the right to sell an authorized generic of Provigil, meaning Teva earns from both ends of the patent spectrum. The company says it has 177 product registrations awaiting FDA approval—120 of these are patent challenges for first-to-market generic rights.
6 Eli Lilly $14.9B up 4.2%
Global revenue: $24.3B (10th); up 5.2%
R&D spend: $5.0B (9th), up 2.0%; 20.6% of rev.
Top brands: Cymbalta ($3.2B), Zyprexa ($2.2B), Humalog ($1.4B), Alimta ($995M), Evista ($707M)
Planned launches: BI 10773 (diab.), dulaglutide (diab.)
Promotional spend: $1.4B (2nd); 9.2% of rev.
Patent expirations: Humalog (2013), Cymbalta (2014), Evista (2014)
Eli Lilly spends the most of the top 20 drugmakers, as a percentage of revenue, on R&D. Unfortunately, R&D output is not necessarily correlated with what you spend, showed a study funded by the Midwest company which was cited by the Sanford Bernstein analyst Tim Anderson. Anderson predicts a bolt-on acquisition. But Lilly's pipeline is slowly improving. After its GLP-1 partnership with Amylin dissolved late last year, dulaglutide moved to the forefront as its lead GLP-1 candidate, and Lilly is aiming for a 2013 filing. Somewhat of a longshot is Alzheimer's candidate solanezumab, which passed an interim safety analysis in January. Recent launch Tradjenta was the third DPP-IV to market and has diabetes giant Januvia to contend with. Patent expirations loom on two megablockbusters—CNS drug Cymbalta and diabetes med Humalog.
7 Roche $14.5B up 5.1%
Global revenue: $46.4B (5th); down 10.4%
R&D spend: $9.1B (2nd), down 5.2%; 19.6% of rev.
Top brands*: Xeloda ($648M), Boniva ($582M), Pegasys ($519M), Valcyte ($325M), Cellcept ($269M)
Planned launches: Pertuzumab (onc.), TDM-1 (onc.)
Promotional spend: $182M (17th); 1.3% of rev.
Patent expirations: Xeloda (2013)
Roche continues to boast a muscular pipeline and a high-performing portfolio of high-science (and high margin) drugs, biologics and diagnostics with negligible exposure to patent expirations (apart from Xeloda, a $648 million drug that loses exclusivity next year). The company recently won approval for Erivedge (vismodegib), for basal cell carcinoma, and just filed pertuzumab for breast cancer. Several other products for various cancers, asthma and atherosclerosis (like CETP inhibitor dalcetrapib) are in late-stage development. The Swiss firm solidified its standing in biologics with its acquisitions of Genentech (2009) and a majority stake in Chugai Pharma (2002), and is now pursuing a hostile takeover of San Diego gene sequencing specialist Illumina.
*Does not include Genentech brands
8 GlaxoSmithKline $14.2B down 6.6%
Global revenue: $43.4B (7th); down 3.6%
R&D spend: $5.9B (7th), down 3.3%; 13.6% of rev.
Top brands: Advair ($4.6B), Lovaza ($899M), Flovent ($709M), Avodart ($525M), Vesicare ($199M)
Planned launches: Relovair (asthma); 444+719 (COPD); GSK1349572 (HIV/AIDS)
Promotional spend: $1.0B (5th); 7.3% of rev.
Patent expirations: Diskus device (2013-25); Avodart (2015), Lovaza (2017)
Despite three new vaccine approvals and a 12% return on R&D investment, GlaxoSmithKline continues to tread rough waters. The number eight pharmaceutical company has seen vaccine and pharmaceutical sales shrink 31% between 2009 and 2011, partly due to patent expirations. The company exhibits a dogged commitment to plan: despite a US government push to vaccinate boys against HPV, the company said girls and women will remain the target group for vaccine Cervarix, yielding the field to Merck's Gardasil; a generic of top seller Advair could launch soon; and the company has also given ground in the OTC market, including selling 17 brands to Prestige Brand Holdings, although it's having trouble unloading weight-loss drug Alli.
9 Amgen $13.1B up 3.1%
Global revenue: $15.6B (15th); up 3.3%
R&D spend: $3.2B (14th), up 10.3%; 20.5% of rev.
Top brands: Enbrel ($3.5B), Neulasta ($3.0B), Epogen ($2.0B), Sensipar ($518M), Xgeva ($343M)
Planned launches: AMG386 (onc.); ganitumab (onc.)
Promotional spend: $346M (15th); 2.6% of rev.
Patent expirations: Neupogen (2013), Neulasta (2015), Epogen (2015), Sensipar (2015)
Amgen has enjoyed a stable of top-earning biologic products. Over the next several years, many of the patents on these products will expire, and the company expects to face competition, including from biosimilars. Teva has already filed a BLA for a Neupogen-like biosimilar. Amgen's ESA drugs Aranesp and Epogen have also been buffeted by new CMS bundling rules and by warnings on their labels. Launches of denosumab drugs Prolia and Xgeva haven't met projections. Luckily for Amgen, top seller Enbrel shouldn't see biosimilar competition for some time—Amgen and ex-US marketing partner Pfizer just locked up protection for another 17 years. Moreover, the Enbrel co-promote expires in late 2013, after which Amgen will pocket overseas revenues for the biologic, as well.
10 Johnson & Johnson $12.1B down 6.2%
Global revenue: $65.0B (2nd); up 5.5%
R&D spend: $7.5B (5th), up 10.3%; 11.5% of rev.
Top brands: Remicade ($3.5B), Procrit ($1.2B), Concerta ($856M), Levaquin ($778), Prezista ($630M)
Planned launches: Canagliflozin (diab.), TMC-435 (HCV), bapineuzumab (Alz.)
Promotional spend: $438M (13th); 3.6% of rev.
Patent expirations: Remicade (2014), Prezista (2016), Zytiga (2016)
J&J's past year can be summed up in one word: recalls. The healthcare products giant had a lot of them, fueling discussions of a company that has lost its luster. This came in addition to lawsuits alleging fraudulent marketing of its antipsychotic Risperdal. The impact of these missteps shows: the government shutdown of a McNeil plant hurt inventory levels, and OTC sales fell 3% in the US last year. But a recent poll showed consumers are still attached to J&J. CEO William Weldon, who was in place during much of the product recalls, was replaced by Alex Gorsky.
11 Sanofi $11.8 down 3.3%
Global revenue: $43.8B (6th); up 3.3%
R&D spend: $6.7B (6th), up 11.7%; 15.3% of rev.
Top brands: Lantus ($2.3B); Eloxatin ($806M); Lovenox ($633M); Taxotere ($243M); Plavix ($196M)
Planned launches: Teriflunomide (MS), visamerin (VTE), Lemtrada (MS), lixisenatide (diab.)
Promotional spend: $477M (12th); 4.0% of rev.
Patent expirations: Plavix (2012), Multaq (2014), Actonel (2014)
The diabetes medication merchant said in February that it expects business to fall off between 12% and 15% this year, as it weathers the aftershocks of patent losses on Lovenox, Ambien CR, Taxotere and Plavix. But it hopes to add diabetes treatment lixisenatide, a GLP-1 agonist scheduled to be filed this year. The GLP-1 field is a crowded one; Sanofi could bump up against Amylin's newcomer, Bydureon. Despite the uncertainty, Sanford Bernstein analyst Tim Anderson praised the company, in part because its patent cliff levels off next year.
12 Abbott $11.5B up 5.5%
Global revenue: $38.9B (8th); up 10.5%
R&D spend: $3.8B (10th), up 8.6%; 9.8% of rev.
Top brands: Humira ($3.5B), Tricor ($1.3B), Niaspan ($1.2B), AndroGel ($1.1B), Synthroid ($657M)
Planned launches: Bardoxolone (renal), elotuzumab (onc.), daclizumab (MS)
Promotional spend: $699M (10th); 6.1% of rev.
Patent expirations: Trilipix/Tricor (2013), Niaspan (2013), Humira (2016)
With mega-earner Humira in its back pocket and a dearth of major patent expirations, Abbott seems well-positioned. Sales rose in 2011, and the company saw out-of-US sales take the lead in its revenue portfolio. In an April research note, Jefferies analyst Jeffery Holford called the company a top pick, citing "impressive top-line results" for its all-oral hepatitis C therapy (in Phase IIb) and positive earnings momentum. Abbott also managed to expand its Humira empire when the EU approved the drug to treat ulcerative colitis. Company plans also include dividing into two this year. The changeover will result in a diagnostics/devices firm called Abbott and a research-based pharma company named AbbVie, now up for sale.
13 Bristol-Myers Squibb $10.9B up 11.2%
Global revenue: $21.2B (11th); up 8.7%
R&D spend: $3.6B (11th), up 5.9%; 17.0% of rev.
Top brands: Plavix ($6.8B), Abilify ($5.2B), Avapro ($952M), Sustiva ($940M)
Planned launches: Eliquis (SPAF); brivanib (onc.); necitumumab (onc.)
Promotional spend: $906M (7th); 8.3% of rev.
Patent expirations: Plavix (2012), Avapro (2012), Abilify (2015)
Bernstein analyst Tim Anderson forsees eight years of flattish growth for BMS. Among the reasons: losing exclusivity of blockbuster drug Plavix this month and pushback from the FDA, which wants more information about its diabetes contender dapagliflozin, which, if approved, would join a crowded market. On tap is the blood thinner Eliquis—the FDA delayed review for this drug, as well, by three months. The firm's recent strategy has included buying biotech Inhibitex in February 2012 and Amira in September 2011, as well as jettisoning non-pharmaceutical brands. Anderson says the sell-offs have made BMS the most "pure play" pharmaceutical company he covers in the US and Europe.
14 Boehringer Ingelheim $7.0B up 9.4%
Global revenue*: $16.5B (14th); down 1.2%
R&D spend*: $3.3B (13th), up 2.0%; 19.8% of rev.
Top brands: Spiriva ($2.4B), Combivent ($1.1B), Pradaxa ($559M), Aggrenox ($471M), Fluticasone ($352M)
Planned launches: Afatinib (onc.), Vargatef (onc.), volasertib (onc.), BI 10773 (diab.)
Promotional spend: $906M (8th); 12.9% of rev.
Patent expirations:
Spiriva Handihaler (2018)
Boehringer Ingelheim is firing on all cylinders, with six products planned to launch over the next two years, the global roll-out of Pradaxa under way and scarcely a patent expiration in sight. The company has a host of oncology and hepatitis C virus treatments in late-stage clinical trials (BI201335/BI207127), and its partnership with Lilly is already bearing fruit on the diabetes front, with Jentadueto having followed Tradjenta to market. The firm has just completed a $350-million expansion in the US, which accounts for 45% of sales. Blood thinner Pradaxa now must fend off competition from J&J/Bayer Xarelto, and maybe soon Pfizer/BMS drug Eliquis (apixaban).
*Global revenue and R&D spend are based on the 2010 financial year, the latest data available at press time.
15 Takeda $6.6B down 1.5%
Global revenue*: $17.5B (13th); down 3.3%
R&D spend*: $3.5B (12th), down 5.4%; 20% of rev.
Top brands: Actos ($3.4B); Velcade ($693M), Dexilant ($555M); ActoPlusMet ($472); Amitiza ($264M)
Planned launches: Alogliptin (diab.), TAK-700 (onc.), Contrave (obesity), peginesatide (anemia)
Promotional spend: $668M (11th); 10.1% of rev.
Patent expirations: Actos (2012)
Takeda is in the teeth of a steep patent cliff, with Prevacid bleeding share and Actos, which accounts for half of US sales, set to lose exclusivity in August. The Japanese firm hopes to overcome these headwinds via its "Transformation into a New Takeda" plan, which includes a new R&D hub in Shonan, streamlining the US sales force (by 1,400 US jobs in 2010 and another 700, announced in January) and acquisitions like last year's $13.7-billion deal for European pharma Nycomed and this year's $800-million deal for URL Pharma, while reaching beyond its heritage in metabolic, oncology (Millennium) and CNS to immunology and inflammation. And the company hopes to grow US sales of Prevacid follow-on Dexilant, Daliresp for COPD, Uloric for gout, cancer drug Velcade and antihypertensive Edarbi. Two late-stage candidates, obesity drug Contrave and DPP-4 inhibitor alogliptin, have run into FDA roadblocks.
* Global revenue and R&D spend are based on the financial year ending March 31, 2011, the latest data available at press time.
16 Mylan $5.6B up 16.7%
Global revenue: $6.1B (19th); up 10.9%
R&D spend: $282M (20th), up 4.6%; 4.8% of rev.
Top brands: Fentanyl ($472M), bupropion XL ($336M), omeprazole Rx ($242M), EpiPen ($226M)
Planned launches: Generic versions of Advair Diskus (resp.)
Promotional spend: $2M (20th); 0.04% of rev.
Patent expirations: N/A
Five years ago, the Pittsburgh generics giant cobbled together an empire through its acquisitions of Dey Pharma, Matrix Laboratories and the Merck KGaA generics business, going from being the No. 3 player in US generics to No. 3 worldwide. Now Mylan is looking to expand in markets where generics are underutilized, including much of Europe, the Middle East and Asia (half the company's revenues come from generics-happy North America), while increasing the number of products it markets from 4,700 to 6,700 by 2015 and pushing into generic biologics. The firm faces some generic erosion of its own, though, as Sanofi and Intelliject will launch a competitor to its lucrative EpiPen Auto-Injector franchise in November.
17 Gilead Sciences $5.5B up 17.0%
Global revenue: $8.4B (18th); up 6.3%
R&D spend: $1.2B (17th), up 14.5%; 14.6% of rev.
Top brands: Atripla ($2.6B), Truvada ($2.0B); Viread ($466M), Ranexa ($320M), Hepsera ($69M)
Planned launches: Cobicistat (HIV/AIDS), "Quad" pill (HIV/AIDS), GS-7977 (HCV)
Promotional spend: $32M (18th); 0.6% of rev.
Patent expirations: Hepsera (2014), Letairis (2015), Viread (2017)
This specialty biopharma firm remains highly competitive, most notably in antivirals. The leader in the field, Gilead launched HIV/AIDS drug Complera last year and filed the "Quad pill" for approval (set for FDA review in August). Complera and Quad represent important advances, and analysts expect both to get approved and to snag the bulk of new patient starts in coming years, although Gilead's top seller, HIV/AIDS med Atripla, is not scheduled to lose exclusivity until 2021 and despite a generic version of Combivir. The firm also leaped ahead in the hotly contested race to market an all-oral/interferon-free hepatitis C therapy, buying biotech Pharmasset for $11 billion and access to that firm's Phase III pipeline asset GS-7977. The company also plays in the cardiovascular arena, where angina drug Ranexa is selling well, and the FDA's removal of a warning from the label of PAH product Letairis could mean higher sales of that drug. Despite a manufacturing shortage, the drug Cayston also plays an important role in treating pseudomonas aerugonisa in cystic fibrosis patients.
18 Novo Nordisk $5.3B up 17.8%
Global revenue: $11.7B (17th); up 9.3%
R&D spend: $1.8B (16th), up 5.9%; 15.4% of rev.
Top brands: Novolog ($1.0B), Levemir ($843M), Novolog Flexpen ($779M), Victoza 3-pack ($457M), NovoSeven ($385M)
Planned launches: Degludec/DegludecPlus (diab.), rFXIII (bleeding), liraglutide (obesity), Turoctocog alfa (haem. A)
Promotional spend: $433M (14th); 8.2% of rev.
Patent expirations: N/A
The Danish diabetes giant continues to soar on North American sales of its modern insulins, in particular. As of November, the company had captured half of the total global insulin market and almost that much of the modern insulin market. Victoza, launched in 2010 for type 2 diabetes, saw meteoric growth in 2011 and became a blockbuster, but faces competition from Amylin's Bydureon and is weighing the development of a once-weekly version to fend off the challenge. The firm has high hopes for its thrice-weekly Degludec, a basal insulin that would take on Sanofi's $5-billion Lantus, and is exploring an obesity indication for Victoza, a possible gold mine. Now if only they could do something about Victoza spoke and bad press magnet Paula Deen.
19 Otsuka $5.2B up 13.0%
Global revenue*: $13.1B (16th); down 2.2%
R&D spend*: $2.0B (15th), up 11.7%; 14.5% of rev.
Top brands: Abilify ($5.2B), Samsca ($48M), Busulfex ($12M), Pletal ($2M)
Planned launches: Sativex (pain)
Promotional spend: $15M (19th); 0.3% of rev.
Patent expirations: Abilify (2015)
The Japanese holding company remains dependent upon its blockbuster antipsychotic drug Abilify, which it co-promotes with Bristol-Myers Squibb. In the fiscal year ending March 31, 2011, the drug provided half of the company's income. Otsuka says its goal is to continue to focus on teaming up with companies for research, with an emphasis on CNS and oncology. The company also noted that the earthquake that rocked Japan and toppled several warehouses did not significantly affect business.
* Global revenue and R&D spend are based on the fiscal year ending March 31, 2011, the latest data available at press time.
20 Forest Laboratories $5.2B up 10.6%
Global revenue*: $4.2B (20th); up 7.7%
R&D spend*: $716M (19th), down 34.9%; 17.0% of rev.
Top brands: Lexapro ($2.9B), Namenda ($1.5B), Bystolic ($383M)
Planned launches: Aclidinium (COPD), linaclotide (IBS)
Promotional spend: $866M (9th); 17.5% of rev.
Patent expirations: Lexapro (2012), Namenda (2015)
Forest's top-selling drug, $2.9-billion SSRI Lexapro, just lost patent protection, and number two drug Namenda's next in 2015. On the other other hand, there's the boffo sideshow that is longtime chief Howard Solomon's ongoing battles with (some would say persecution by) HHS and activist investor Carl Icahn. The upside is the company launched Teflaro in March, following Daliresp and Viibryd, and has already filed NDAs for aclidinium (COPD) and linaclotide (IBS).
* Global revenue and R&D spend are based on the fiscal year ending March 31, 2011, the latest data available at press time.


text:
Extreme Truck & Trailer Repair provides:
24 Hour Emergency Road Service for Semi Trucks
KTR 24/7 Mobile Service provides:
24 Hour Road Service for Semi Truck Breakdowns
Love's 24 Hour Truck Tire Care & Roadside Service can dispatch a certified technician to your location, or you can stop by when on our lot. Our centers are equipped with cutting-edge tools and equipment to meet your truck care needs. We carry an extensive selection of tires to fit every need and budget:
BRIDGESTONE - FIRESTONE - MICHELIN - BFGoodrich
We've also partnered with Interstate Batteries, Centramatic on-board tire balancing and RoadPro truck parts to keep you moving.
You'll find our strategically located Truck Tire Care locations wherever you need them most.
24 Hour Roadside Assistance
It's Important to Pilot Flying J Truck Care that you get back on the road confident and feeling like you made the right choice. Through our network of 150 locations, whether you're on the road or on-site, our focus is what you need today.
For Roadside Assistance Call 888-997-1034

subset: commoncrawl


text:
Moderator: Community Team
Lindax wrote:Hi all,
Trying to create a mailing list for +2000 Speed Games:
+2000 Speed Games (6, 7, 8 Player - Esc)
doublediamond wrote:5 player standard, no spoils, chained, fog, 100 rounds.
a few maps i've been wanting to play. let's see if they fill up.
standard pw.
Game 11804077 Northwest Passage
Game 11804080 Transsib 1914
Game 11804082 Triple Alliance
Game 11804087 Austro-Hungarian Empire
RashidJelzin wrote:hey,
just came back from a long pause - can someone pm me the pw please?
slickstm wrote:Can someone email me standard pw....thanks.
Users browsing this forum: No registered users


text:
Morningstar Corn Dogs Make Triumphant Return To Grocery Shelves
They're back! Around this time last year, we investigated the sudden disappearance of Morningstar Farms' delicious vegetarian corn dogs and hot dogs from grocery shelves. Consumers seem to care very deeply about this product. We're happy to report that the corn dogs, at least, are back on the Morningstar Farms website, and a reader has spotted them in the wild.
Catastrophegirl sent us these photos, noting: "Apparently they are popular, since they were almost all gone." This creates a mental picture of local vegetarians buying armfuls of boxes, then going home to spend the evening in a corn dog-eating frenzy.
The site tells me that the only retailer carrying the full-size corn dogs near me are suburban Walmarts, and no one carries the mini dogs locally. Have any of this product's fans found and taste-tested the new version? What did you think?
Morningstar Farms® Veggie Corn Dogs [Morningstar Farms]
Want more consumer news? Visit our parent organization, Consumer Reports, for the latest on scams, recalls, and other consumer issues.


text:
Article Summary: This article provides information on best practices for Hyper-V clusters using iSCSI - configuring Do Not Allow Cluster Network Communication on This Network on iSCSI networks
It is recommended to select Do no allow cluster network communication on this network on the iSCSI NIC's of a Hyper-V failover cluster server. Follow the steps in the solution to achieve this goal.
1. Open the Windows Failover Cluster Manager by opening Server Manager, click on Tools and click Failover Cluster Manager.
2. Choose Networks and expand the tree by clicking the arrow next to Networks.
3. Right-click on the the iSCSI-1 network and select Properties.
4. Ensure Do not allow cluster network communication on this network is selected.
5. Click OK to save the settings.
6. Repeat steps 3 through 5 on any remaining iSCSI networks.
Additional information about best practices for Hyper-V failover clustering can be found on TechNet.
Article ID: SLN289398
Last Date Modified: 08/27/2014 08:52 AM
Thank you for your feedback.


text:
I'm just going to very quickly submit two lessons on some very famous and well-loved wrestlers from the WWE. In the past I submitted a tutorial on Jeff Hardy and that lesson blew up like an atomic bomb. Today I thought it would be cool to submit "how to draw Matt Hardy", step by step which happens to be Jeff's brother. Together the duo became "The Hardy Boyz" and this was during the years 1998-2001. His full name is Matthew Moore and as of right now he is thirty six years old and if you ask me, Matt has a totally different look than his brother Jeff. Jeff and Matt also founded an organization called OMEGA, which is short for "Organization of Modern Extreme Grappling Arts" which was established in 1997. His careers were started in the wrestling business and for so long all Matt did was perform for his fans. When the end of the Hardy Boyz came to pass, he started doing some self-promoted work without his brother Jeff. Nowadays he still wrestles and as far as I know he was supposed to be released from the WWE because Matt no longer wanted to be associated with the organization. When September of last year rolled around the WWE stated that Matt Hardy is to be released from his contract. For some extra bio information on Matt Hardy, did you know that when he was in school he was quite the athlete? So much so he played baseball through almost all of his school years, and then he even played some football as well. Once he became a senior all his sports with baseball and football came to an end. Anyways, you will have an awesome time learning "how to draw Matt Hardy", step by step. Just to let you guys know this WWE wrestler has been requested by so many people so I went ahead and filled those requests. Have fun ya'll when tackling this tutorial. I'll be back soon.
DragoArt members upload artwork and drawing tutorials! They are also allowed to leave comments on tutorials, profiles, etc. Many more features, as well; it's way better than just being a boring guest! Register Now!


text:
In my last post, I introduced Microsoft's new Deep Zoom technology and showed how we could use it to zoom way in on a large family photo. This time, I'm posting a collage of 191 photos of my Dad that lets you zoom way in on each individual photo. If you've never seen Deep Zoom in action before, it's well worth taking a look. I think that you'll be amazed at the experience. Follow the link below to get started.
This collection includes 191 photos of my Dad, John Sexton, spanning his entire life: 1933-2005. Many of the original scans are fairly high resolution, so as you zoom in, you'll be able to see some wonderful details.
How to use Deep Zoom to view the collection:
- Follow the link below to bring up the page
- Download and install Silverlight, if requested (it's quick)
- Use the scroll wheel on your mouse to zoom in and out
- Depending on your internet connection, you may need to wait a bit after zooming for the image to sharpen
- To start with, zoom all of the way out so that you can see the entire collection
- Then explore by zooming in on individual photos
- You can also pan (slide) by holding the left mouse button down and dragging
Here's the collection: John Sexton Deep Zoom Collection
(If you don't want to go actually run the demo, you can watch a short run-through on YouTube — the resolution isn't nearly as good as the real thing, but you'll get the idea).
Here are some specific things to go look for in the collection (think of this as a treasure hunt):
- There's a lot of detail in the buddha in the 3rd row
- Look at the kids' faces in the class photo, 2nd row, leftmost photo
- Find the thumbprint on the photo of John w/the bow and arrow, 1st row
- Look at the detail on the old printing presses, 2nd from last row, 6th photo from left
- Look at the detail in John's face, 5th from last row, 2nd photo from the right (face in his hands)
- Find Uncle Tom in a ballerina outfit, somewhere in the 7th row
- In the 1st row is a photo of John with brother Jerry during the first snowfall of 1938. Can you identify the car in the background?
- Zoom in on the 1st photo, 5th row, and enjoy incredible color in the photo of Mt. Fuji from 1953
- Elsewhere on the 5th row, you'll find a car. Can you read the make?
- In the 7th row, you'll find a photo of John serving some brandy. Can you read the label? What time is it?
- 2nd from the last row, 3rd from left, John holds his granddaughter Lucy's hand. What color are her eyes?
- Can you find the greenish photo in the center of the grid that features John, an antique steel trash baler and an old Ford 8N tractor?
Here are a few other interesting details about this collection:
- The original collection is comprised of 191 scanned or digital photos
- Deriving from the original 191, the Deep Zoom collection itself is comprised of 18,433 separate images
- The collection takes up 1.44GB of disk space
What do family historians out there think about this as a technique for exploring a collection of family photos?


text:
Deaver Herbarium (ASC) is home to more than 110,000 dried museum specimens of ferns,
conifers, and flowering plants collected primarily in northern Arizona and the adjacent deserts. As a permanent scientific repository, the Deaver Herbarium was assigned a permanent acronym, ASC, when NAU was called Arizona State College. The herbarium is a public facility
that supports a wide array of research projects and educational programs.
students and researchers by providing historical and contemporary specimens for study
> More
Support courses taught in Biological Sciences and create opportunities for graduate and
undergraduate research and student curatorships
> More
resource for students, professional botanists, private consultants, and the Flagstaff community
> More


text:
Perry, Elissa L. (ep248)Skip to content Skip to main navigation
226C Thmps
Office Hours:
Wednesdays: 4:30-5:30
Educational Background
- Ph.D., Carnegie Mellon University
- M.S., Carnegie Mellon University
- B.S., Trinity College
Scholarly Interests
- The role of personal characteristics (e.g., age, generational membership, gender, race, disability) in human resource judgments, organizational behavior, and employment outcomes
- Diversity training and sexual harassment awareness training
Selected Publications
Perry, E.L., Hanvongse, A., & Casoinic, D. (2013). Making a case for the existence of generational stereotypes: A literature review and exploratory study. In R. Burke, C.Cooper, & J. Field (Eds.), Handbook on Aging, Work, & Society. London: Sage Publications.
Perry, E.L., Dokko, G., & Golom, F. (2012). The aging worker and person-environment fit. In J.W. Hedge and W.C. Borman (Eds.), The Oxford Handbook of Work and Aging. Oxford University Press (pp. 187-212).
Perry, E.L., Kulik, C.T., Bustamante, J., & Golom, F.D. (2010). The impact of reason for training on the relationship between "Best Practices" and sexual harassment training effectiveness. Human Resource Development Quarterly, 21(2), 187-208.
Perry, E.L., Kulik, C.T., & Field, M.P. (2009). Sexual harassment training: Recommendations to address gaps between the practitioner and research literatures. Human Resource Management, 48(5), 817-837.
Kulik, C.T., Roberson, L., & Perry, E.L. (2007). The multiple category problem: Category activation and inhibition in the hiring process. Academy of Management Review, 32, 529 - 548.
Perry, E.L., & Parlamis, J.D. (2005). Age and ageism in organizations: A review and consideration of national culture. In Konrad, A.M., Prasad, P., & Pringle, J.K. (Eds.), Handbook of Workplace Diversity. London: Sage publications.
Goldberg, C., Finkelstein, L.M., Perry, E.L., & Konrad, A.M. (2004). Job and industry fit: The effects of age and gender matches on career progress outcomes. Journal of Organizational Behavior, 25, 807-830.
Perry, E. L., Hendricks, W., & Broadbent, E. (2000). An exploration of access and treatment discrimination and job satisfaction among college graduates with and without physical disabilities. Human Relations, 53, 923-955.
Perry, E.L., Davis-Blake, A., & Kulik, C.T. (1994). Explaining gender-based selection decisions: A synthesis of contextual and cognitive approaches. Academy of Management Review, 19, 786-820.
Professor Perry received her B.S. in Psychology in 1987 from Trinity College, Hartford, CT. She received an M.S. in 1989 and a Ph.D. in 1991 in Organizational Psychology and Theory from Carnegie Mellon University. Professor Perry was an Assistant Professor in the Institute of Labor and Industrial Relations at the University of Illinois from 1991-1998 and a visiting fellow in the Psychology Department at Goldsmiths College, London England in the spring of 1999. Professor Perry is an active member of the Academy of Management and Society for Industrial and Organizational Psychology and serves on the Editorial Board of the Journal of Management. She teaches in the Masters, Ph.D. and executive management programs at Teachers College. Professor Perry has also consulted to educational, nonprofit, and for-profit agencies.
Dr. Perry's workgroup>>
Member, American Psychological Association
Member, Society for Industrial Organizational Psychology
Editorial board member, Journal of Management


text:
I've been doing my own investigations into sounds coming from underneath Ambergris (or maybe just less used chambers of my fevered mind), and after long hours spent sifting through the ruins of the Borges Bookstore, I have come upon a particularly curious piece of apocrypha, said by some to be a folk song of the mushroom-like gray cap people, and by others to be a fraud committed by a particularly untalented and violently defrocked Truffidian priest:
The Sounds of The Silence*
Hello gray caps, my old friends
I've come to live with you again
Because a vision softly creeping
Left its spores while I was sleeping
And the vision that was planted in my brain
Still remains
Within the sound of The Silence.
In restless dreams I walked alone
Beneath these streets of cobblestone
My stomach churned with aching cramps
I turned my collar to the cold and damp
When my eyes were stabbed by the green of
A glowing light
That split the night
And filled me a dread of silence.
And in the glowing light I saw
Ten thousand gray caps, maybe more
Mushrooms talking without speaking
Mushrooms hearing without listening
Mushrooms writing songs that voices never shared
And no one dared
Disturb the sound of The Silence.
'Shrooms, said I, you do not know
Silence like a cancer grows
Hear my words that I might teach you
Take my arms that I might reach you
But my words like silent spores all fell
And echoed
In the wells of silence.
And the dwellers bowed and prayed
To the spore-born God they made
And I felt my mind warming
With a voice that was forming
And the voice said: The words of the prophets
Are written on the city's walls
And Zamilon's halls
And whisper'd in the sounds of The Silence.
*From section III of The Hoegbotton Guide to the Early History of the City of Ambergris by Duncan Shriek: "...upon Aquelus' return, the city of Ambergris lay empty, not a single living soul to be found upon any of its boulevards, alleyways, and avenues, nor within its many homes, public buildings, and courtyards." I refer you to Shriek's text for further details, though I do recommend consuming it with large grains of salt and frequent reference to more recent attempts to put Shriek's endeavors into perspective.


text:
The new permanent host site for the IMW and the IAW special events
Important notice - For a great number of years, the IMW and now the IAW have scrounged web hosting where ever it could find it at no cost. This has resulted in a service which has become less and less reliable - it has also generated lots of unnecessary work for me and now the team, frantically trying to maintain it. Our most recent outage (off line for +10 days) has prompted us to look at alternatives - one of which is to at least organise a domain name, so if one site has an outage we can instantly divert your enquiries to an alternative server. We would also like to apologise for the difficulties, I know some have had getting to the site, but hopefully our new site will see an end to these issues.
I am glad to say we have been donated long term server hosting, on a reliable commercial server and also donated a domain name of our choice -http://www.radio-amateur-events.org/.
We should like to thank Chris G8PUT for giving us server space for a number of years.
Museums Weekends 2014
International Air
Ambulance Week 2014


text:
News and Events: Press releases
Second Arab Regional Media Forum concludes in Dubai
Deliberation during the 3-day meeting has re-invigorated the sense of urgency surrounding the issue, as it prompted expressions from media individuals and guest organisations to more thoroughly explore, unveil and confront the socioeconomic and cultural factors hampering girls' access to schooling as well as to boost their longer-term chances for development and participation in society.
Among panelists and guests were renowned media professionals and human rights experts, as well as regional and international NGO collaborators from countries like Morocco, Algeria, Tunisia, Egypt, Sudan, Jordan, Syria, Yemen, UAE and Oman.
Following a review of the Arab charter drafted last year, media participants today agreed to individual contracts whereby they commit to undertaking different activities to support dissemination of child rights stories, including girls' education. Implementation and follow-up constitute the immediate response to the plenary proposal to strengthen regional media networking around children-related issues.
The event was organized by UNICEF, in partnership with the World Food Programme, UNESCO, the Dubai Humanitarian City, the Dubai Press Club, Al Bayan Newspaper, the Arab Institute for Human Rights and the Center for Arab Women for Training & Research (CAWTAR).
Quality Education: A renovated concept
UNICEF Regional Education Adviser for the Middle East and North Africa, Dr. Malak Zaalouk said Arab countries' efforts to achieve quality education need to go beyond the one-dimensional approaches such as hiring teachers, or providing textbooks.
"New models need to be devised so that education systems can take account of a wider range of factors from ensuring water, toilets, playing areas, and supporting girls to learn how to learn, to the more demanding aspects of safeguarding and protecting children, and especially girls, from environments that threaten their dignity and physical wellbeing", Zaalouk noted.
"It is also essential that we develop systems for measuring learning achievements in its broader sense, -- including life skills as well as children's creative capacities", she added.
In perfect harmony with the subject under discussion, the Dubai Forum also made reference to the World Press Freedom Day on May 3rd and UN Secretary General's statement highlighting that "as agents of change ( ) media have a powerful influence on human behaviour". On the occasion, Secretary General Kofi Annan stated that "information is also becoming more diverse. Mainstream media reporting, for example, is being supplemented by participatory media".
Cultivating long-lasting partnerships with the Arab media
During the closing ceremony, the Dubai Forum today reiterated the value of media as catalysts for crucial transformations and also the need to mobilize communities to get and keep Arab girls in school.
The Dubai-based O3 Productions, which is the production and acquisition arm of MBC Group of channels that includes al Arabiya News channel, in close cooperation with UNICEF, has embarked on a multi-country co-production with exclusive features and special reports looking at the status of girls' education in Yemen, Sudan, Morocco and Egypt.
"We look with great excitement at the opportunity ahead to associate with UNICEF and lend the best of our energies to this project. Hopefully, this contribution will help Arab societies look at girls' education as a vital investment with the highest possible dividends for the future", said Fadi Ismail, General Manager of O3 Productions.
The MBC girls' education programme follows similar successful UNICEF-supported initiatives in the recent past with the BBC and Al Jazeera.
For further information, please contact:
M. Anis Salem, Regional Communication Adviser, UNICEF MENA-RO
E-mail: firstname.lastname@example.com Mobile: 962-79-557-9991
Wolfgang Friedl, Communication Officer UNICEF MENA-RO,
E-mail: firstname.lastname@example.com Mobile: 962-79-573-2745


text:
Melrose Boy Scout Troop 68 Forum
Melrose Boy Scout Troop 68 Message Board
Log in to check your private messages
Log in
Oswald's mini adventures
Melrose Boy Scout Troop 68 Forum Forum Index
Dungeons & Dragons Game Synopsis Site
View previous topic
View next topic
Joined: 21 Mar 2006
Posts: 703
Posted: Fri Nov 30, 2007 12:52 am
Post subject: Oswald's mini adventures
This is the story of a man. His name? Oswald Iambdnd. I have always wondered, what do DnD characters do in their off time? Sleep, drink, visit the brothel? My only answer to this is: I rolled a 6.
Oswald sat at the local bar, still celebrating after a well played card game. Slamming the glass mug into the counter, a loud, unquivering belch exploded from his mouth, and the whole saloon froze in time for just a split second to look at our drunken hero before continuing on. The barkeep grabbed Oswald's mug and filled it up, shrugging his shoulders when Oswald gulped the thing down in seconds. It wasn't his problem that Oswald had to much money to spend, and he was making a nice profit on whatever this guy's problem was.
After twenty more rounds of this the whole bar was now watching Oswald chug down another pint of alcohol and another belch would escape from his thirsty mouth. Tomorrow would be worse then the 9th level of heck, but Oswald didn't care, he was to rich to do that. It was then, that a spark hit the embers in the bar. Another loud noise came from Oswald, but this time from his nether region. It droned on and on, kept a low but constant tone. The seconds dragged on, and still it continued. Finally after nearly a minute the beast suddenly and instantly stopped, and the bar was silent. A middle age man broke this forever silence, throwing up his hands and shouting at Oswald at the top of his lungs, proclaiming he was sick and tired of this.
His hands suddenly flew into a series of gestures, and the path between the man and Oswald cleared as the man muttered under his breath. Oswald had seen a mage before, heck he lived with one and he knew that this was trouble. But he did not care; he was to rich to have trouble. Standing up, Oswald let out a giggle before making some gestures somewhat similar to the mage and copying the movements.
A lesson for those of you who are uneducated with the magic arts, one is that mages require extreme dexterity with their hands to make all the magical gestures. Oswald, while very in tune with his body, is drunk and is lucky to be standing. The second lesson is that mages study for their whole life time for these magical words for a reason so it literally burns into their brain. Oswald has hung around a few mages, but he has only opened a book a handful of times, much less a spell book.
Finally, magic is conjured by the mage from within himself. Not some weak thing like clerics who are basically doing a giant prayer to the gods so they will heal something, this is pure energy. Oswald had some energy like all regular men, maybe even a bit more, but not flowing from his body like mages.
But luckily for Oswald the liquor he was drinking was watered down, the movements were exactly the same as his fighting technique, and the words muttered were actually a saying his mother use to tell him.
He failed spectacularly.
The mage let out a mighty blast of energy, heading straight for Oswald. Oswald only had one chance and he failed, and blast came from him and exploded a few feet from him, diverting the blast in some random direction and sending chicken feathers and tar all over the bar. Within seconds every feathered man, women, and dog were fighting each other. Stumbling out of the bar, Oswald wandered the streets, knocking on houses until he found his way to the guild.
Name: Oswald
Status: ????
Class: Fighter
Level: 6
17 stength
11 intellegence
12 wisdom
17 dexterity
15 constitution
15 charisma
49 hit points
Back to top
Joined: 09 Mar 2006
Posts: 1479
Location: Minneapolis MN
Posted: Fri Nov 30, 2007 12:55 pm
Post subject:
Back to top
Display posts from previous:
All Posts
1 Day
7 Days
2 Weeks
1 Month
3 Months
6 Months
1 Year
Oldest First
Newest First
Melrose Boy Scout Troop 68 Forum Forum Index
Dungeons & Dragons Game Synopsis Site
All times are GMT - 5 Hours
Jump to:
Select a forum
Melrose Troop 68 Discussion Forum
Scouting Message Board
Melrose Scout Productions Podcast
Dungeons & Dragons Message Board
Dungeons & Dragons Game Synopsis Site
post new topics in this forum
reply to topics in this forum
edit your posts in this forum
delete your posts in this forum
vote in polls in this forum
Powered by
© 2001, 2005 phpBB Group


text:
Google is relatively well know for embracing third-party developers. Where iOS forces users to stick with default browsers and email clients, use limited sharing options and keep their home screen just how Apple likes it, Google excels in handing over the keys to the kingdom. This goes for services too, where developers have been able to leverage products like Google Maps to make fantastically fast and accurate location-based software. This year at Google I/O, I'd like to see Google give third-party developers access to another one of their amazing services, Google Now. If you thought Google's automated digital assistant of the future is impressive now, just think of the possibilities.
Released today for iOS, Osito is a Google Now clone for Apple products. It not only looks the same, but functions the same as well. You plug in some accounts, and Osito uses your location, email and calendar to bring you useful information exactly when you need it. When I first heard about Osito, I thought it seemed like a great idea, to beat Google out the door and try to establish an active user base as soon as possible. But Google is so powerful, and has so many people working on Now, there's no way Osito could possibly keep up. And then I read something unique about Osito: it's going to be opened up to third-party developers.
Instead of just relying on what Osito itself can offer, the app will let third-party developers have at it. As Ellis Hamburger writes in his look at Osito on The Verge, "You can imagine future integrations where Osito's API ties in with IFTTT to text your spouse when you've arrived at work or send a tweet when you're on the way home. You could set up Foursquare to ping you with recommendations when you land in a new city."
Google's restaurant and places ratings are great, and Google+ is one of my networks of choice, but both may not always be my first choice. I'd like to get Foursquare or Yelp cards in Google Now, because my friends use Foursquare and Yelp. When it's one of my friends birthday's, I'd like to be able to wish them a good day on Twitter or Facebook. I'd like to choose what service provides me with the information I see in Google Now, something that feels like right up Google's alley.
The rate at which Google has rolled out features to Google Now has been meticulous. They've made sure not to push too much at once, and provided just the right amount of control to users when it comes to the appearance of cards and how frequently they're displayed. Developers looking to utilize Google Now would have to follow strict design and notification guidelines, but that wouldn't be a problem. If Google made Now integration easy enough, third-party services would be clamoring at the chance to put their cards, and their notifications, exactly where you need them, when you need them.
It would be like giving a steroid injection to a handful of already incredibly useful apps, pushing Google ahead of the competition even further. And that's not even really diving in to the location-aware triggers aspect third-party developers could bring to the table. The creator of Osito, Bill Ferrell, mentioned in an interview that he set up a trigger with Osito to turn on a lava lamp when he enters his office. The possibilities there are endless.
We're bound to see a lot of great things at Google I/O 2013, but third-party Google Now access is easily at the top of my list. The deep system integration and one-stop-shop information hub aspects of Google Now already causes me to use it more than apps that provide similar information, even when those apps provide information that's closer to what I'm looking for. Google Now is easier, so most of the time I just don't bother. But there are times when I have look for information elsewhere.
With third-party integration, Google Now would be all I ever need, and a whole lot more.


text:
Good food guide
Nadine's veggie pizza
Preparation time: 5 minutes
Cooking time: 5 minutes
2 sliced wholemeal rolls or wholemeal soda bread
1 small tin chopped tomatoes
1 teaspoon dried mixed herbs
4 sliced fresh mushrooms
85g half-fat cheddar cheese (sliced or grated)
1 sliced red or green pepper
1 small sliced red onion
Small pinch of pepper
Preheat grill to a medium heat. Toast the rolls lightly on both sides.
Spread the tomatoes over the top of the toasted bread. Scatter the remaining ingredients, divided equally between the four portions.
Place under the grill and cook until the cheese is bubbling. Serve immediately with a salad.
Good food guides
Family food interactive guides
Health eating self-assessment Could your diet be putting your health at risk? Find out with this short test.
Five a day meal planner This meal planner makes it easy to get your 5 a day.
Food allergies self-assessment Determine whether you have a food allergy or an intolerance.


text:
Currency Displayed in
Below are the available bulk discount rates for each individual item when you purchase a certain amount
Salisbury Rugby SRS performance shorts. Solid black performance rugby short by Steamroller Rugby Supply. Lightweight and durable quick-dry synthetic material coupled with stretch zones engineered for the Game.
Strategically-placed inserts expand and contract with the ups and downs of tackles, rucks, mauls, and scrummage. The design allows for free, uninhibited movement without binding. Straight-cut design prevents extra material for would-be tacklers to grab.
Rubberized waistband to keep the jersey in the shorts. No side pockets; inside hanging pocket for mouthguard. Subtle embroidered "Steamroller Rugby" branding on the right thigh, Salisbury logo on the left thigh.
This product hasn't received any reviews yet. Be the first to review this product!
All prices are in USD.


text:
Roller Skates
Puffin Books, 1936 - Juvenile Fiction - 186 pages
A Newbery Medal Winner!
Growing up in a well-to-do family with strict rules and routines can be tough for a ten-year-old girl who only wants to roller skate. But when Lucinda Wyman's parents go overseas on a trip to Italy and leave her behind in the care of Miss Peters and Miss Nettie in New York City, she suddenly gets all the freedom she wants! Lucinda zips around New York on her roller skates, meeting tons of new friends and having new adventures every day. But Lucinda has no idea what new experiences the city will show her.... Some of which will change her life forever.
"A refreshingly lively and genuine story."—The New York Times
From inside the book
19 pages matching Miss Lucy in this book
Where's the rest of this book?
Results 1-3 of 19
What people are saying - Write a review
User ratings
|5 stars
|4 stars
|3 stars
|2 stars
|1 star
LibraryThing ReviewUser Review - klburnside - LibraryThing
Roller Skates is the story of Lucinda, a wealthy young girl in New York City in the 1890s. Her parents spend a year in Italy, leaving Lucinda in the care of two local women. Lucinda enjoys her year of ... Read full review
LibraryThing ReviewUser Review - afrazier13 - LibraryThing
This book is about a young girl who is sent to boarding school while her parents vacation in Italy. She ventures out through thy city on her roller skates making lots of new friends and learning new ... Read full review
An Introduction to Lucinda
Up Drives Mr Gilligan
Friend at Large
8 other sections not shown
Other editions - View all
Common terms and phrases
afternoon Aleda Aunt Ellen Aunt Emily bambino Bath bun borrow Trinket brought Browdowski Bryant Park Caliban called Christmas cinda Coppino desk diary dinner Doctor Hitchcock dolls door downstairs Eighth Avenue elegant Emily's eyes face folding bed friends Gedney House Gilligan griddle bread guess hand hansom cab happened head Heigh-O inside Jerry Hanlon Johanna Kate Seredy keep knew laughed little girl looked Louis Sherry Luanda's mother Lucin Lucinda found Lucinda skated Lucinda thought Lucinda took LUCINDA WYMAN mam'selle mama mama and papa Miss Brackett Miss Lucy Miss Nettie Miss Peters morning never nice Night Owl old Rags-an'-Bottles parlor Patrolman M'Gonegal play princess Pygmalion roller skates Ruth Sawyer sewing shouted sleep song Spindler stood street supper tell Tempest theatre things told Tony Tony's tree Trinket's father Twelfth Night Uncle Earle underdrawers young


text:
Man of the Year
Carlos Tevez (Manchester City)
Carlos Tevez owes this award to Mario Balotelli. That is not to say that the Italian is a more deserving Man of the Year – it is the fact that if he had not kept his cool to assist Sergio Aguero for the Premier League-winning goal on May 13, everything would have been different for Tevez.
Starve a club of glory for 44 years and they will become desperate. Irrational.
Manchester City were slipping back in the title race when Tevez returned to action. Roberto Mancini, who is to tactical planning what a toaster is to lockpicking, relied upon individual brilliance to win games but most of his brilliant individuals were burned out.
|Robin van Persie
The year in which the Dutch Destroyer transformed from injury-prone talent to best-in-the-world-bothering goal volcano. So good that nobody noticed his useless Euro 2012 and so strong that he survived that vicious attack by Ashley Williams.
As Lionel Messi blitzed his fearsome goal-rampage all year long, number-crunchers have rarely been more in demand as they were hired to dig up the next unlikely feat. "No player has scored more goals on Tuesdays than Messi!" "He's the first man to net two with only one shot!" They've earned their crust.
Leon Osman
In a tough year for football, seeing Osman finally win an England cap was a cathartic victory for all the little guys out there. MTY salutes you, Leon.
Rejuvenated, Mancini's men stole the title from Manchester United in a fashion more dramatic than a 14-year-old girl's Facebook messages. Everything was fine.
Fine? Why was everything fine? Why did City and all their fans just shrug and mutter "hey, crazy Carlos. What ya gonna do?"
Tevez refused to do his job and went on a golfing tour of South America for four busy months. That's not adorably crazy, that's grossly unprofessional. Setting your bin on fire and buying trampolines from John Lewis is adorably crazy.
So again, Tevez owes this award to Balotelli. If Super Mario hadn't laid the groundwork for City fans accepting extraordinary behaviour, the Argentine would have been hounded out before he could slink back into training.
Instead, he is welcomed by all because, when he finally did bother to show up, he won them a trophy. Glory finally burying the body of football's principles, stuffing its corpse roughly into a well-dug grave beneath the 18th green. Carlos Tevez is football's Mr 2012.
Quote of the year
"We've left ourselves a two-goal cushion to climb"
- Petr Cech after Chelsea lose 3-1 to Napoli in the first leg of their Champions League clash. Turns out that cushions are, in fact, easy to climbStar Wars: A Blue Hope
A long, long time ago in a tax bracket far, far away... the CHELSEA EMPIRE is in chaos. On the planet Mustamfar Bridge, their once-mighty fortress is crumbling, spewing dodgy defending everywhere like lava.
ROBERTOBI-WAN KENODI MATTEO and ROMANAKIN SKYWALKER are waging a fierce duel across the fiery landscape, their lightsabers flashing and hissing like the VIP guests at a footballers' Christmas party after midnight.
|Goalkeeper: Ali Al Habsi. The only reason why Wigan didn't go down last year, he's now seeking a new challenge as the main reason why they probably will.
Defence: The Society of Black Lawyers. Ever-present. (Plus Stewart Downing at left-back.)
Midfield: Marouane Fellaini and his hair. That'll probably do.
Forwards: Grant Holt - the working man's champion in 2011-12, deserved an England call-up in the summer, said as much, didn't get it, got in a huff, hustled his club for more money and then just picked up where he left off. Fair play. Partnered by Gervinho.
ROBERTOBI-WAN: You have done that yourself! Your anger and lust for power have already done that. By putting so much faith in that pathetic cartoon of a man, Fer Fer Torrinks, you caused all this!
ROMANAKIN: You were the chosen one!
ROBERTOBI-WAN: No, Romanakin, I was the only one left! I conquered the galaxy for you; we could have ruled it as father and son! But you wanted Han Guardiolo instead – he'll never join you!
ROMANAKIN: I see through your lies! With you gone, I can bring peace, freedom, justice and security back to the Empire! If I build it, Guardiolo will come!
RAFAEODA: (emerging from the darkness) FACHT, that is.
ROBERTOBI-WAN: Aligning with the enemy, Romanakin? I've got a bad feeling about that. If you strike me down, I will become more powerful than you can possibly imagine!
ROMANAKIN: Hardly. You'll get the Swansea job when Michael Laudrup moves up the ladder, maybe.
A jump. A lightsaber flashes. Silence.
Photo of the Year
Best ex-thing
Euro 2012
Euro 2012 was a solid tournament, perhaps a six-and-a-half or maybe seven out of 10. A good time was had by all, though more in the exciting group stage than the only-really-worth-it-for-Balotelli knockouts.
In future years, however, we will remember it as a marvel, a show-stopping explosion of footballing joy. For future editions of the competition will push upon our faces a pair of glasses so rose-tinted that bees will be trying to pollenate our eyes.
|English football
On the pitch, standards are slipping like John Terry playing a high line. There's fun to be had but the Premier League has well and truly had its pants pulled down in the Champions League. Even Ligue 1 is catching up! Off the pitch... just grow up, everyone, please.
Emmanuel Adebayor
Last year, he was the glue holding Spurs together as the league's most entertaining side. Now he's a red-card-in-waiting playing second fiddle to Jermain Defoe's revolutionary 'false false nine' poacher role.
Disastrous! Losing club captain Van Persie has, as expected, destroyed the Gunners - to the extent that they are further up the table than they were at this stage of last season. What is it that you want back exactly?
So it was fun but now it's gone. We'll just have to pretend that Poland and Ukraine was the perfect send-off for a delightful but now essentially defunct institution – and there were some incredible highlights, like the Antonin Panenka comeback tour and Nicklas Bendtner's pants.
Anyway, we'll always have Paris. And London. And Munich. And Bucharest. And...
Hashtag of the Year
Football is still learning how to deal with Twitter. The relationship has improved, undoubtedly, but there are plenty of flare-ups as the sport reluctantly gets to grips with modernity.
Who could forget the foul-mouthed rant from Ashley Cole as he labelled the FA a "#BUNCHOF[REDACTED]"? Or Rio Ferdinand accusing [REDACTED]? Or [REDACTED] Heskey [REDACTED] spoon [REDACTED]?
Twitter is a great force for good, uniting players, journalists and fans like never before. It can also be a horrible place, where anonymity makes morons feel brave enough to write racial abuse or post Photoshopped pictures of John Terry celebrating other people's victories.
|Things that should have happened in 2012 but didn't:
Swansea City releasing a parody 'Danny Graham Style' video
Brendan Rodgers playing all the characters in 'Being: Liverpool'
Chelsea winning the Club World Cup (too soon?)
The people needed hope. The people needed joy. The people needed cereal. And so Morrison began a solemn mission to try lots of different kinds of cereal and judge each one to find the best. And he did it with a quite brilliant way with words.
"First things first! The box itself is ridiculous!" he wrote when evaluating Golden Nuggets. "Draws you in from what feels like a mile away! Your eyes lock on and you can't take them off! Till you grasp the box in your hands! Beautiful and captivating!
"Once the milk washes its self over this graceful cereal! Something amazing happens! It remains unexplained! The crunch of the little nuggets as you bite into them and the flavour of the luscious milk! BAFFLING! Best yet! ... 4/5"
Thrilling and different, Morrison has proved himself the Froot Loops of footballers on Twitter. There can be no higher praise.


text:
Christopher M. Dekaney, PhD
- In December 2008, The National Institute of Diabetes and Digestive and Kidney Diseases awarded a 4 year Career Development Grant to Dekaney for his project investigating "The Role of FGFR1 and FGFR2 in Repair of Damaged Intestinal Epithelium." The project began in January 2009.
- In September 2009, Dekaney was awarded a two-year grant supplement for career development. The project, entitled "The role of FGFR1 and FGFR2 in Repair of Damaged Intestinal Epithelium," covers the period 09/01/2009 – 08/31/2011 and was awarded under the American Recovery and Reinvestment Act of 2009.
- In August 2009, McLean was selected by the Harold Amos Medical Faculty Development Program of The Robert Wood Johnson Foundation to receive a four-year mentored grant. His project, Smooth Muscle Cell Related Mechanisms of Pulmonary Hypertension in Congenital Diagphragmatic Hernia, will be mentored by Dr. Cam Patterson, chief of UNC's Division of Cardiology.
- Amy Marzinsky, , BSN, RN, OCN
Clinical Research Coordinator


text:
By Tim Bedley
In 2007, I set out to transform my classroom into something special.
No more butcher paper covering the walls.
No more cold hard desks and plastic chairs.
I wanted my classroom to be more like Starbucks than a hospital;
more like a model home than a waiting room.


text:
Find an Urgent Care Near You.
Whether it's after your doctor's office is closed, or any time when you can't wait to see a doctor, UPMC Urgent Care is here to help.
Our walk-in clinics provide a full range of medical services for people of all ages, 12 hours a day, 7 days a week.
Our urgent care locations throughout western Pennsylvania are open from 9 a.m. to 9 p.m., no appointments necessary.
Board-certified physicians, physician assistants, and CRNPs at UPMC Urgent Care centers provide:
At UPMC Urgent Care, our doctors and clinical staff are dedicated to providing you and your family with expert, express care.
Open 9 a.m. to 9 p.m.
No appointment needed
Most insurance accepted
Free parking
Video Library
Follow us on Twitter


text:
The academic chairman at the center of the long-running academic fraud at UNC-Chapel Hill is now cooperating with an investigation led by Kenneth Wainstein, according to his attorney.
"Dr. (Julius) Nyang'oro has given his full and complete cooperation to the investigation being conducted by the independent counsel," said attorney Bill Thomas of Durham.
Nyang'oro faces a criminal fraud charge related to the scandal for accepting $12,000 in special summer pay for a 2011 class that didn't meet. Thomas has said his client did not commit a crime and would fight the charge if the case went to trial.
Thomas would not disclose what information Nyang'oro has so far provided to Wainstein, a former top U.S. Justice Department official hired in February by UNC-Chapel Hill and the UNC system to conduct the third investigation led or backed by UNC into the case. Wainstein could not be reached.
Nyang'oro's cooperation would mean that Wainstein now has commitments from the two people who have taken nearly all of the blame for the scandal involving lecture-style classes that never met. Nyang'oro's longtime department manager, Deborah Crowder, agreed to cooperate with the investigation at its outset, after Orange County District Attorney Jim Woodall said he would not pursue charges against her.
In the three years since the scandal first erupted, Nyang'oro and Crowder have never talked publicly about the case.


text:
Jessica Alba Does Even More Dancing in Sin City 2
"It was very, very difficult, and you'll see why."
When we think assless chaps, we think Matthew McConaughey. But let's not forget that Jessica Alba was dancing in stripper pants long before McConaughey even thought to design his for Magic Mike. And she could very well steal back her thunder when she returns as exotic dancer Nancy in Sin City 2. "I had to learn a bunch of dance sequences for it," Alba told us at a Sundance party for A.C.O.D. "I do a lot more dancing in this one." So much more that she needed three months to prep for the part. "It was kind of crazy," she said. "It was very, very difficult, and you'll see why." We are intrigued. As for the comedy she was in Park City to promote (she plays one of the adult children of divorce), she said she was "grateful" to work with such a funny cast. "I tried to be cool around, like, Amy Poehler and Adam Scott," she said. "But I'm not."


text:
Executive Summary
I've made a couple versions of DIY tarp beaks, posted here, and here. This generated enough interest for 2Q to suggest that he and the Zipper Queen ZQ might offer a version of this, based on the second of my designs.
2Q and ZQ did some sewing and sent me a prototype for evaluation.
Of course I had to make a video, "Breaking Wind, An Introduction to the 2Q/ZQ GrizzBeak."
I put the beak up on these tarps
- OES MacCat Deluxe
- Hennessey Silnylon Hex
- Hennessey Asymmetric Diamond
- JRB 11'x10'
The Diamond shape tarp was interesting. Because of the asymmetry one beak side covers the side of the tarp whose tie-out is nearest very nicely. The other beak side is not long enough to cover the far side exactly. It will cover almost all of it (not shown) but can be staked out wide to assist in breaking the wind (that is shown).
Other footage I shot but which didn't work out so well because of failing light is to fasten the beak sides inside the JRB tarp, using Grip Clips. This makes sense if for example the beak faces west but the wind comes from the east, and so might otherwise catch between the beak side and tarp, where the beak lies on the side of the tarp.


text:
Lost the Twenty20 match by 12 runs, needed 22 off the last over chasing 169 and I think Hutton played for his 50 just quietly. Won the youth match by 5 runs in abit of a reversal where Matts Aussies needed 9 runs from 3 overs but just didn't have the wickets in hand.
Rest In Peace Craigos
Won my Youth Match quite well despite having only one bowler over poor. Looking forward to my one day matches today/tomorrow.
President of SKAS - Kat is King | Proud member of CVAAS - One of the best | LRPLTAS - Rosco rocks!
Go Tigers!
R.I.P. Fardin & Craig
Pool A
Otago vs. Male Models
caves_beachcc vs. Asterix XI
Pool B
Wheelabarrowback vs. Central Districts
The Winners vs. ZP and HF
To be played on the 25th of October. First team written is at home. Go for your life.
Last edited by 33/3from3.3; 18-10-2007 at 01:52 AM.
Around the Grounds
After 2 overs:
Central Districts v The Winners
The Winners has won the toss and elected to bowl
End of over 2 (2 runs) - Central Districts(2-0) RR 1.00
Eime 1 (4b), Walker 1 (8b), Kharbanda 1-0-2-0
Zero Pillars and Hero Fillers v Wheelabarrowback
Wheelabarrowback has won the toss and elected to bowl
End of over 2 (7 runs) - Zero Pillars and Hero Fillers(10-1) RR 5.00
Maithripala 1 (2b), Aysha 7 (4b), Doherty 1-0-7-1
caves_beachcc v Male Models
caves_beachcc has won the toss and elected to bat
End of over 2 (4 runs) - caves_beachcc(12-0) RR 6.00
Brookes 4 (5b), Ambler 4 (9b), Saker 1-0-4-0
Otago v Asterix XI
Asterix XI has won the toss and elected to bat
End of over 2 (4 runs) - Asterix XI(4-1) RR 2.00
Alfred 2 (3b), Chung 1 (7b), Huntington 1-0-4-1
Adam and I looking in trouble both losing an early wicket. Knowing my team, its all but over . Too early to tell anything really, just bored.
Feels so rejected, hate you so much Paddy.
The man, the mountain, the Mathews. The greatest all rounder since Keith Miller. (Y)
Jaffna Jets CC (Battrick & FTP)
RIP WCC and CW Cricket
Member of the MSC, JMAS and CVAAS
Please tell me that's in jest. Sorry buddy, you just said nothing.
2 down now, in a bit of strife.
You didn't say what your team name is. Look i'm sorry i am only human. Humans make mistakes. I don't hate you i didn't leave you out on purpose.
119/4 after 20, itstl. What are your bowlers like geg? I've got one reasonable and four average. Batsmen are relatively crap, one average and five ordinary. Sold a reasonable bowl/average bat allrounder for 191k yesterday though.
Smith is 101/3 after 22. After being pegged back to about 3.5 RPO they are firing up. His opener, Walker started off very slow, but he's taken off just now and then slowed down again...and just completed his 50.
There are currently 1 users browsing this thread. (0 members and 1 guests)


text: Wall decals for kitchens and bathrooms bring function and style to the kitchens and bathrooms, two of the busiest rooms of the house! With peel and stick tiles to create classy back splashes, calendar and message board decals perfect for the fridge, and even modern clock decals, your kitchens and baths will be beautiful and organized! We also have stylish kitchen wall decals to invigorate your space in all different colors and themes.


text:
Patriots return to practice field
Patriots return to practice field
Fans got their first glimpse of Tom Brady and the Patriots back on the practice field Tuesday as the team held a voluntary offseason workout.
New receiver Danny Amendola, signed by the Patriots in the wake of Wes Welker's departure, worked out with Brady.
Linebacker Jamie Collins, the Patriots' top draft pick, was on the field for the workout.
Head coach Bill Belichick, beginning his 14th season in New England, oversaw the practice.


text: After letting the cat out of the bag about the 2011 Aprilia Dorsoduro 1200, speculation almost immediately began about what other machines in the 2011 Aprilia line-up could be using the 1200cc mill as well. While we still await word on a Shiver 1200, the company from Noale seems set to debut a restart to its well-aged Tuareg line. Expected to be unveiled at the EICMA show later this year, the 2011 Aprilia Tuareg 1200 was hinted at by Roberto Colaninno, head of the Piaggio Group, during the company's Milan HQ launch party.


text:
Anatomic Pathologists examine tissue or cells removed from the patient's body, either surgically or in less-invasive procedures such as needle biopsies, for microscopic evidence of cancer and other diseases; or, in the case of forensic pathologists, to determine the cause of the patient's death in an autopsy.
The Anatomic Pathology Laboratories are located on the Hawthorne Campus. Please see the individual listings for the directors and managers of each laboratory.
Please click items on the list below to learn more about the specific Anatomic Pathology Laboratories; including hours of operation, contact numbers, personnel, and available tests and services.
If you are searching for blood bank, clinical chemistry, hematology, immunology, and\or microbiology, they are apart of the Clinical Pathology Laboratories.
Click here for a list of Investigation Pathology Laboratory Services.
All Anatomic Pathology LabsAll Clinical Pathology LabsReference Labs and Consultations
Tel: -5080
[email protected]
Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.


text:
Last edited by Richard; 23-04-2006 at 05:25 PM.
Appreciating cricket's greatest legend ever - HD Bird...............Funniest post (intentionally) ever.....Runner-up.....Third.....Fourthcricket player"; "Bob"), 1/11/1990-15/4/2006
(Accidental) founder of Twenty20 Is Boring Society. Click and post to sign-up.
And i didn't even know him
they guy loved cricket so much, its just really shocking and tragic when someone so young passes away.
It's just so tragic. I feel quite numb. All that potential gone in a flash.
My thoughts go to his family, can hardly imagine what they must be feeling like.
Cricket Web's current Premier League Tipping Champion
- As featured in The Independent.
"this was Argentinas heaviest defeat in the group stage of a World Cup since losing 6-1 to Czechoslovakia in 1958. It is also the first time they have failed to win either of their opening two matches at a World Cup for 44 years. Sampaolis players, in other words, were creating history here" - The Guardian's Stuart James on Croatia's 3-0 dicking of the South Americans
No way... i didnt really know him that well but its so sad.. gonna miss the guy
February 10th 2009 <3
Rest In Peace Fardin
Rest In Peace Sazza
Originally Posted by BoyBrumby
its wierd...never knew the lad, enjoyed reading some of the things he used to say, visited the website of the league he played in a couple of times to see if he was 'for real' etc....and yet I feel really sad right at this moment. My thoughts are with his family and friends
Really makes you think about life and stuff!!!!!
rave down, hit the ground
MSN: firstname.lastname@example.com
Bob? Dead?
Really shocking and eye-opening, just terrible.
Thoughts with his family.
Same way i feel.Originally Posted by Swervy
how can i feel sad for someone i never knew?
Because anyone with a heart feels sad when a young life is taken that doesn't deserve to be taken?
Really tragic news there - I can't quite believe it. We used to make fun of him from time to time, but we all knew he was a really good guy at heart, and clearly he was a very talented cricketer. A huge shock. Thoughts are with his family. RIP.
Last edited by Barney Rubble; 23-04-2006 at 02:04 PM.
Originally Posted by Richard
it was probably a rhetorical question really!!!!!
Rest in peace.
Everyday life is only an illusion behind which lies the reality of dreams." - Werner Herzog
Friedrich Nietzsche | Werner Herzog | Joy Division | Ludovico Einaudi | History | Peep Show
There are currently 1 users browsing this thread. (0 members and 1 guests)


text:
Conservative Corner: American dream?
By Nancy Carlton
I have one problem to deal with while writing my column today: I need lots more space - I need an entire page. Whew!
As a Republican, I am veritably jumping up and down in place, trying to encourage, urge, pester, and otherwise goad our "first Republican majority in 138 years" to follow through with the mission with which we entrusted them, and not be hornswoggled into caving to pressures from the establishment. They have done a good job with vital new laws to protect "life, liberty, and the pursuit of happiness".
As a board member of Arkansas Carry, I stay pretty buzzed about all the issues regarding our Second Amendment rights and the related bills that have been in the forefront of late. There has been real progress made in Arkansas on this issue, and I thank our legislators for doing the right thing.
However, on a national level, we have absolute predators stalking our rights to self-defense in the personages of Barack Obama, Sen. Dianne Feinstein and a whole parade of pantywaists who believe that only the police and the military should be allowed to use the equipment that a true patriotic American can tell you is a God-given mechanism with which to guard the people that we hold most dear — our families.
The shortage of available firearms, and especially ammunition, has already become a common problem faced daily by people seeking to purchase self-defense items.
My friend and fellow Arkansas Carry board member, Nicholas Stehle, posted on Facebook:
"I walked into a gun shop and they had .22LR and .22 shorts on the shelf, both in small denominations and in large quantities. I bought two cases of .22LR. Then I woke up from my dream. Dang!"
I told him, "That's the new American dream."
Those of us who have been attempting to stock up somewhat on items that we know may soon no longer be legally available because of Obama's war on the Second Amendment know that the shelves are already bare, the prices are higher on what is available, and America is watching to see if any Second Amendment rights will remain at all in a few months. The battle is on.
As a freedom-loving Conservative, I am aware that the Big Government vs. Small Government struggle is already in at least the "third quarter of the game" and the plan to totally tear down the republic and replace it with Socialism by those on the extreme left is being implemented bit by bit, using all the nasty moves and false arguments they can muster.
In the past, I have mentioned the book, "1984," by George Orwell, as a good source of exposition of what an all-powerful government can do.
Also of immense value is "Animal Farm" by the same author, which shines a light on the actions of politicians vs. citizens.
However, in reading the new book by Stephen Moore, titled "Who's the Fairest of Them All?," I have come across excerpts from a Kurt Vonnegut story that dramatizes brilliantly what government does in its misguided quest to make everyone "equal." It is an exaggeration, of course, but makes the point spendidly:
"The year was 2081, and everybody was finally equal. They weren't only equal before God and the Law. They were equal every which way.
Nobody was smarter than anybody else. Nobody was better looking than anybody else. Nobody was stronger or quicker than anybody else.
All this equality was due to the 211th, 212th, and 213th Amendments to the Constitution, and to the unceasing vigilance of agents of the United States Handicapper General."
The story is titled, "Harrison Bergeron", from a collection called "Welcome to the Monkey House".
In the world of Harrison Bergeron, the government forced each individual to wear "handicaps" to offset any advantage they had, so that everyone could be truly and fully equal. Beautiful people had to wear ugly masks to hide their good looks. The strong had to wear compensating weights to slow them down. Graceful dancers were burdened with bags of bird shot.
Harrison Bergeron was a very special individual. He was above average in every way. Seven feet tall, very intelligent, strong and blessed with abilities, he was a unique problem for the government handicappers. They impaired him with a huge set of earphones, eyeglasses with wavy lenses, and scrap metal hung all over him, to the point that he looked like a walking junkyard.
In the story, Harrison finally arrives at the place in his life where he rises up against his oppressors and tears away his encumbrances - to remarkable and astonishing results.
Sadly, in the story, the "Handicapper General" storms onto the scene and kills Harrison. No one must be allowed to break from the government, of course.
I beg you, patriots and lovers of freedom, we must stand our ground. Learn from the parable of Harrison Bergeron and the prophetic works of fiction that sound more like reality every day.
Nancy Carlton is a resident of Saline County. Her column appears each Wednesday in The Saline Courier.


text:
|Thread Tools
|Display Modes
|26th October 2011, 07:46 PM
New Member
Join Date: Sep 2010
Location: Boston MA
Posts: 14
GO 133 as progression board?
Hoping to get some advice or feedback...
I own a Rio M, recently put a larger (58cm) fin on it. Interesting in progressing to a 2nd board, something lighter than the Rio and bit more "oomph" -- speed, early planing, performance, etc.
How does the Go 133 stack up? There is one available used, at a fair price. I am 5'7" 155lb. male, and currently on the Rio M I can tack/slow-speed jibe, intermediate footstraps, use the harness (but not fully committed to it yet)...my catapults are "falls" to the side... Usually if planing, I am in front footstrap (w/ rear foot on the board). Sail in light/med winds, sail sizes 5.7-7.5, don't use the centerboard much anymore. Some beachstarting, no waterstarting yet...
How would the Go 133 fare given my skill/progression level? At my weight, is it uphaulable? Easily uphaulable? Can it be used in light winds.... or would a 150L volume be better?
Also available is older Futura 144L. My understanding is this is lighter board, but more fragile. Any pros/cons or recommendations? My interest is flat-water/chop. No waves for me
Thanks -
Last edited by imbrooks; 26th October 2011 at 07:50 PM.
|26th October 2011, 08:49 PM
Dream Team - School Guru
Join Date: Aug 2006
Posts: 2,202
Hi Brooks,
The GO 133 will be OK, but at your weight you might look for something in the 110-115 liter range.
That will be more in line with your sail sizes.
At 155 lbs, you can uphaul any board > 100 liters and probably uphaul 90-100 liter boards but not as easily.
There is a dilemma here.
You have small to mid size sails for the light/medium conditions you suggest,and if the winds are steady @ > 12 knots, you (at your weight) can go a bit smaller and still get some planing performance.
But, for truly light winds (I.R. < 12 knots, a wider board and larger rigs would be what you need to plane more of the time.
The Futura 144 sounds like it's more the "light wind planer" you want (vs the GO 133), but getting an 8.5 m2 rig would sure help with your light winds.
Yes, lighter boards are a bit more fragile, but when you get fully back in the footstraps (you will need this skill for either the Futura or GO 133) and are not getting catapaulted rig onto the nose, you won't have any durability issues with the Futura.
As far as what works to plane in < 12 knots...... wider boards and larger sails!
Last edited by Roger; 27th October 2011 at 04:44 AM. Reason: Changed @<12 kn to @>12 kn
|26th October 2011, 09:48 PM
Join Date: Aug 2006
Location: Dallas, Texas USA
Posts: 799
Roger offers good advice.
There is never one correct answer because ones progression in windsurfing depends on many variables. Things like - typical winds, number of days sailing per year, plus dedication and commitment to mastering the sport. 95% of us never "master" the sport, but we become hooked on the enjoyment and excitement of the sport.
So, look at yourself and project where you think you want to be in a year or two. Basically, a board in the 110-115 range as Roger suggests is a good recommendation if you "know this is your sport". If you are content with just enjoying the outdoors and cruising around with little stress, the the bigger boards may be a better option.
The smaller boards take a higher level of commitment to master, but the payoff can be much greater. Many of us that have a couple of decades under our belts, usually have between two and four boards so we can maximize our time on the water in any conditions. Where you live also plays a huge role in what gear you have because of the winds and venues. Boston means a shorter sailing season so it's hard to accumulate a lot of days. I don't know about the winds there, but that's where it may be to your advantage to check out what the other Boston windsurfers are using most of the time. Keep it up and you will be hooked. Careful it doesn't mess up your family life.
Formula 160; iSonic 111; HiFly Move 105; Tiga 263; '85 Mistral Superlight.
Maui Sails TR 11.0; 9.2; 8.4; 7.6; 6.6; Maui Sails Switch 6.0; 5.2; Maui Sails Global 4.5; 4.0.
|26th October 2011, 11:23 PM
New Member
Join Date: Sep 2010
Location: Boston MA
Posts: 14
Guys, thanks for the feedback. Let me 'drill down' a little further.
Roger -- I'll take your comment as a "yes" that 133L is plenty of volume. I don't think I'm ready to go down to 110-115 yet. I'm coming from the relative comfort and dryness of a 200L board . Also, wouldn't a 110L board need some decent wind. At this point in my progression, 25+knots scares the cr*p out of me still...
Granted, I need to get a bigger (ie 8.5m2) sail next season... given that, how much more early planing/performance will I get from a Futura vs. Go? The Go is pretty much brand new (2010). The Futura is 2007, well-used but no repairs to the board. Priced similar to each other.
Ken, I'm pretty sure "this is my sport", but I also have family considerations. So I'm more of a TOW guy and happy to just get out and cruise around, w/o being full-fledged fanatic w/ 4board quiver. Although Rio + SUP + new board would put me at 3 already....
|27th October 2011, 12:11 AM
Join Date: Sep 2010
Posts: 70
Are your keeping the RIO?
If yes, you should follow Rogers advice. I'm at your technical level, but heavier at 210lb. I tried a 139l GO and don't feel like buying one since it is similar in usage to my Kona longboard. And I find that a longboard is better in low wind since it is here very inconsistent. A longboard is better in these conditions since you never need to swim back to shore, and it is much nicer below planning threshold.
I am now using a 115l Starsurfer (similar to Kode Tufskin) that I bought for the kids. At my weight, it is difficult to uphaul, and I'm in fact focusing on waterstarts now. But once running, it is much nicer in the chop when powered on my 6.0. A 115l board for you would be great since it will be quite different from your RIO, while being uphaulable.
|27th October 2011, 01:19 AM
New Member
Join Date: Sep 2010
Location: Boston MA
Posts: 14
Sailboarder --
Aargh, this seems conflicting advice I contacted one shop, the owner recommended going w/ a 140-150L board as a progression.
My fear w/ 110L range is that I'd need strong winds to have fun w/ it? I don't want to buy a board that only functions in "nuclear" conditions.
Probably I should wait til Spring and try to demo different sizes before deciding. Then again, I probably should not have gotten into wsurfing in the first place..
|27th October 2011, 04:53 AM
Dream Team - School Guru
Join Date: Aug 2006
Posts: 2,202
If you get the larger sail, you can still use it just fine on a 110-115 liter board.
You can get a wider 110-120 liter board that will plane significantly earlier.
Almost any > 100 liter board can be used with your 5.7 m2 and 7.5 m2 rigs, and any board > 115 liters (and fairly wide (I.E. > 75 cm) will work with all of your sails, abeit better with the 7.5/8.5.
For > 20 knots of wind, you would need a smaller board and probably could sail up to 22 knots with your
5.7 well tuned for high winds.
Sounds like you need a smaller board (you are light in weight @ 155 lbs.) but the normal range of your windspeeds is >10- <20 knots which suits the 110-125 liter boards prefectly.
Also suits you sail sizes for an advancing sailor. Might want to pick up a good 6.5 m2 at some point as there's a bit of a gap from 5.7-7.5 particularly is the 5.7 is a freeride sail and the 7.5 is a free race sail.
Hope this helps,
« Previous Thread | Next Thread »
|Thread Tools
|Display Modes
Linear Mode
|Similar Threads
|Thread Starter
|Last Post
|Wave board versus Slalom board
|Free Forum
|16th October 2011 02:52 AM
|Progression for a 10 year old
|Windsurfing School
|8th July 2011 12:14 PM
|Please freeride board 115L 85kg rider Futura 111L and different board
|Free Forum
|3rd June 2009 02:04 PM
All times are GMT +7. The time now is 05:59 AM.


text:
Free UK delivery & returns. Shop online 24/7!
You have no items in your shopping cart.
3 Item(s)
Regular Price:
Special Price
Special Price
Regular Price:
Special Price
Iutta is an iconic contemporary women's handbags, shoes and accessories brand with a signature folk design. All our creations are inspired from our heritage and core beliefs that are translated through a personal touch into exclusive collections. At Iutta, we approach every new line with the same level of commitment to craftsmanship and innovative design that is synonymous with the fashion brand's vision. Our leather products which reinterpret stylish symbols have became a trademark in the fashion industry.
Copyright IUTTA 2018 Privacy PolicyCookie Policy